Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9582454 | 0.77 | ASH1L (0.34) | — | |
| SCHEMBL3666835 | 0.71 | GABRA1 (0.40) | GABRA1GABRB2AKR1B1MEN1KMT2A | |
| SCHEMBL22482014 | 0.68 | GABRA1 (0.47) | GABRA1GABRB2AKR1B1MEN1KMT2A | |
| SCHEMBL10759141 | 0.68 | AHR (0.46) | GABRA1GABRB2 | |
| SCHEMBL5174789 | 0.67 | GABRA1 (0.42) | GABRA1GABRB2AKR1B1MEN1KMT2A | |
| SCHEMBL19856499 | 0.67 | GABRA1 (0.42) | GABRA1GABRB2AKR1B1MEN1KMT2A | |
| SCHEMBL7288932 | 0.66 | HPGD (0.35) | L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL1969683 | 0.66 | CA12 (0.38) | — | |
| SCHEMBL959953 | 0.66 | TRIM24 (0.39) | MAPTGAAALDH1A1 | |
| SCHEMBL5824091 | 0.66 | GABRA1 (0.58) | GABRA1GABRB2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686985-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005039563-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | claimed |
| EP-1476167-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | Novartis AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2004037266-A1 | COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | claimed |
| WO-2003066062-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | claimed |
| WO-2001085696-A1 | BUTENOIC ACIDS DERIVATIVES AND THEIR USE IN THE TREATMENT OF RHINITIS | NOVARTIS AG (CH) | 2001-11-15 | — | — | WO | claimed |
| EP-1686985-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005039563-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-1476167-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | Novartis AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004037266-A1 | COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003066062-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| WO-2001085696-A1 | BUTENOIC ACIDS DERIVATIVES AND THEIR USE IN THE TREATMENT OF RHINITIS | NOVARTIS AG (CH) | 2001-11-15 | — | — | WO | disclosed |